TARO-DESVENLAFAXINE TABLET (EXTENDED-RELEASE)
Страна: Канада
Език: английски
Източник: Health Canada
Данни за продукта
(SPC)
19-10-2022
Понастоящем някои документи за този продукт не са налични, можете да изпратите заявка до нашата служба за клиенти и ние ще ви уведомим веднага щом успеем да ги получим.
Изпрати заяв.
Изпрати заяв.
Активна съставка:
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE)
Предлага се от:
TARO PHARMACEUTICALS INC
АТС код:
N06AX23
INN (Международно Name):
DESVENLAFAXINE
дозиране:
50MG
Лекарствена форма:
TABLET (EXTENDED-RELEASE)
Композиция:
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50MG
Начин на приложение:
ORAL
Броя в опаковка:
15G/50G
Вид предписание :
Prescription
Каталог на резюме:
Active ingredient group (AIG) number: 0152509001; AHFS:
Статус Оторизация:
APPROVED
Дата Оторизация:
2022-10-20
Данни за продукта
PRODUCT MONOGRAPH
PR TARO-DESVENLAFAXINE
desvenlafaxine extended-release tablets
50 mg and 100 mg desvenlafaxine (as desvenlafaxine succinate
monohydrate
)
Antidepressant
Taro Pharmaceuticals Inc.
Date of Revision:
130 East Drive
OCT 19, 2022
Brampton, Ontario
L6T 1C1
Submission Control No.: 264187
_________________________________________________________________________________________
_Taro-Desvenlafaxine (desvenlafaxine succinate monohydrate) Product
Monograph _
_Page 2 of 52_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFOR
M
ATION
.............................................................................
3
SUMMARY PRODUCT INFORMATION
...................................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................................
3
CONTRAINDICATIONS
..............................................................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................................................
4
ADVERSE REACTIONS
............................................................................................................................11
DRUG INTERACTIONS
.............................................................................................................................21
DOSAGE AND ADMINISTRATION
.........................................................................................................24
OVERDOSAGE
...........................................................................................................................................27
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................................28
STORAGE AND STABILITY
....................................................................................................................31
SPECIAL HANDLING INSTRUCTIONS
.
Прочетете целия документ
